Linking Molecular Diagnostics to Molecular Therapeutics: Targeting the PI3K Pathway in Breast Cancer

Seminars in Oncology

Volumn 30, Issue 5 SUPPL. 16, 2003, Pages 93-104

  Mills, Gordon B ^a   Kohn, Elise ^b   Lu, Yiling ^b   Eder, Astrid ^b   Fang, Xianjun ^b   Wang, Hongwei ^b   Bast, Robert C ^b   Gray, Joe ^b   Jaffe, Robert ^b   Hortobagyi, Gabriel ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CC 1779; CETUXIMAB; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; DNA DEPENDENT PROTEIN KINASE; EVEROLIMUS; GEFITINIB; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; RAPAMYCIN DERIVATIVE; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ATAXIA TELANGIECTASIA; BREAST CANCER; CAENORHABDITIS ELEGANS; CANCER CELL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE; CLINICAL TRIAL; CONFERENCE PAPER; DEPHOSPHORYLATION; DROSOPHILA MELANOGASTER; GLUCOSE METABOLISM; HUMAN; METASTASIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 10744230387     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.08.011     Document Type: Conference Paper

References (96)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003
2. Jeong H, Mason SP, Barabasi AL, et al: Lethality and centrality in protein networks. Nature 411:41-42, 2001
3. Ho Y, Gruhler A, Heilbut A, et al: Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature 415:180-183, 2002
4. Ideker T, Thorsson V, Ranish JA, et al: Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292:929-934, 2001
5. Hartwell LH, Hopfield JJ, Leibler S, et al: From molecular to modular cell biology. Nature 402:C47-C52, 1999 (suppl)
6. Brazil DP, Hemmings BA: Ten years of protein kinase B signaling: A hard Akt to follow. Trends Biochem Sci 26:657-664, 2001
7. Leevers SJ, Vanhaesehroeck B, Waterfield MD: Signalling through phosphoinositide 3-kinases: The lipids take centre stage. Curr Opin Cell Biol 11:219-225, 1999
8. Chan TO, Rittenhouse SE, Tsichlis PN: AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 68:965-1014, 1999
9. Lawlor MA, Alessi DR: PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114: 2903-2910, 2001
10. Stein RC: Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer 8:237-248, 2001
11. Mills GB, Lu Y, Fang X, et al: The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis and therapy. Semin Oncol 28:125-141, 2001
12. Paradis S, Ruvkun G: Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 P13 kinase to the DAF-16 transcription factor. Genes Dev 12:2488-2498, 1998
13. Kozma SC, Thomas G: Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. Bioessays 24:65-71, 2002
14. Scheid MP, Woodgett JR: PKB/AKT: Functional insights from genetic models. Nat Rev Mol Cell Biol 2:760-768, 2001
15. Persad S, Attwell S, Gray V, et al: Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci U S A 97:3207,3212, 2000
16. Yoganathan N, Yee A, Zhang Z, et al: Integrin-linked kinase, a promising cancer therapeutic target: Biochemical and biological properties. Pharmacol Ther 93:233-242, 2002
17. Chan TO, Tsichlis PN: PDK2: A complex tail in one Akt. Science: Signal Transduction Knowledge Environment PE1, 2001
18. Dan HC, Sun M, Yang L, et al: Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 277:35364-35370, 2002
19. Zhou BP, Hung MC: Novel targets of Akt, p21(Cip1/ WAF1), and MDM2. Semin Oncol 29:62-70, 2002 (suppl 11)
20. Shin I, Yakes FM, Rojo F, et al: PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 8:1145-1152, 2002
21. Gottlob K, Majewski N, Kennedy S, et al: Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15:1406-1418, 2001
22. Lu Y, Lin Y, LaPushin R, et al: The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18: 7034-7045, 1999
23. Plas DR, Thompson CB: Cell metabolism in the regulation of programmed cell death. Trends Endocrinol Metab 13:75-78, 2002
24. Kang H, Schneider H, Rudd CE: Phosphatidylinositol 3-kinase p85 adaptor function in T-cells. Co-stimulation and regulation of cytokine transcription independent of associated p110. J Biol Chem 277:912-921, 2002
25. Chan TO, Rodeck U, Chan AM, et al: Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell 1:181-191, 2002
26. Rintelen F, Stocker H, Thomas G, et al: PDK1 regulates growth through Akt and S6K in Drosophila. Proc Natl Acad Sci U S A 98: 15020-15025, 2001
27. Biondi RM, Kieloch A, Currie RA, et al: The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J 20:4380-4390, 2001
28. Webster MA, Hutchinson JN, Rauh MJ, et al: Requirement for both Shc and phosphatidylinositol 3′ kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol 18:2344-2359, 1998
29. Downward J: Role of phosphoinositide-3-OH kinase in Ras signaling. Adv Second Messenger Phosphoprotein Res 31:1-10, 1997
30. Chang HW, Aoki M, Fruman D, et al: Transformation of chicken cells by the gene encoding the catalytic subunit of P13 kinase. Science 276:1848-1850, 1997
31. Aoki M, Schetter C, Himly M, et al: The catalytic subunit of phosphoinositide 3-kinase: Requirements for oncogenicity. J Biol Chem 275:6267-6275, 2000
32. Aoki M, Blazek E, Vogt PK: A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 98:136-141, 2001
33. Jimenez C, Jones DR, Rodriguez-Viciana P, et al: Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J 17:743-753, 1998
34. Borlado LR, Redondo C, Alvarez B, et al: Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 14:895-903, 2000
35. Janssen JW, Schleithoff L, Bartram CR, et al: An oncogenic fusion product of the phosphatidylinositol 3-kinase p85beta subunit and HUMORF8, a putative deubiquitinating enzyme. Oncogene 16:1767-1772, 1998
36. Philp AJ, Campbell IG, Leet C, et al: The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61:7426-7429, 2001
37. Cuevas BD, Lu Y, Mao M, et al: Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J Biol Chem 276:27455-27461, 2001
38. Shayesteh L, Lu Y, Kuo WL, et al: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99-102, 1999
39. Hu L, Zaloudek C, Mills GB, et al: In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6:880-886, 2000
40. Hu L, Hofmann J, Lu Y, et al: Inhibition of phosphatidylinositol 3‴-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62:1087-1092, 2002
41. Cheng JQ, Altomare DA, Klein MA, et al: Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene 14:2793-2801, 1997
42. Bellacosa A, de Feo D, Godwin AK, et al: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64:280-285, 1995
43. Nakatani K, Thompson DA, Barthel A, et al: Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274: 21528-21532, 1999
44. Malstrom S, Tili E, Kappes D, et al: Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus. Proc Natl Acad Sci U S A 98:14967-14972, 2001
45. Hutchinson J, Jin J, Cardiff RD, et al: Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21:2203-2212, 2001
46. Orsulic S, Li Y, Soslow RA, et al: Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1:53-62, 2002
47. Shioi T, McMullen JR, Kang PM, et al: Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22:2799-2809, 2002
48. Condorelli G, Drusco A, Stassi G, et al: Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A 99:12333-12338, 2002
49. Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947, 1997
50. Steck PA, Pershouse MA, Jasser SA, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362, 1997
51. Li DM, Sun H: TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57:2124-2129, 1997
52. Singh B, Ittmann MM, Krolewski JJ: Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer 21:166-171, 1998
53. Bose S, Wang SI, Terry MB, et al: Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 17:123-127, 1998
54. Feilotter HE, Coulon V, McVeigh JL, et al: Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 79:718-723, 1999
55. Garcia JM, Silva JM, Dominguez G, et al: Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 57:237-243, 1999
56. Teng DH, Hu R, Lin H, et al: MMAC1/PTEN: Mutations in primary tumor specimens and tumor cell lines. Cancer Res 57:5221-5225, 1997
57. Freihoff D, Kempe A, Beste B, et al: Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer 79:754-758, 1999
58. Rhei E, Kang L, Bogomolniy F, et al: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57:3657-3659, 1997
59. Sakurda A, Suzuki A, Sato M, et al: Infrequent genetic alterations of the PTEN/MMAC1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney, and ovary. Jpn J Cancer Res 88:1025-1028, 1997
60. Ueda K, Nishijima M, Inui H, et al: Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers. Jpn J Cancer Res 89:17-21, 1998
61. Chen ST, Yu SY, Tsai M, et al: Mutation analysis of the putative tumor suppression gene PTEN/MMAC1 in sporadic breast cancer. Breast Cancer Res Treat 55:85-89, 1999
62. Whang YE, Wu X, Suzuki H, et al: Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 95:5246-5250, 1998
63. Salvesen HB, MacDonald N, Ryan A, et al: PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 91:22-26, 2001
64. Zhou XP, Gimm O, Hampel H, et al: Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157:1123-1128, 2000
65. Perren A, Weng LP, Boag AH, et al: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155:1253-1260, 1999
66. Bose S, Crane A, Hibshoosh H, et al: Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 33:405-409, 2002
67. Nelen MR, van Staveren MC, Peeters EA, et al: Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 6:1383-1387, 1997
68. Marsh DJ, Dahia PL, Zheng Z, et al: Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 16:333-334, 1997
69. Starink TM, van der Veen JP, Arwert F, et al: The Cowden syndrome: A clinical and genetic study in 21 patients. Clin Genet 29:222-233, 1986
70. Andrulis IL, Bull SB, Blackstein ME, et al: neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16:1340-1349, 1998
71. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
72. Cuevas B, Lu Y, Watt S, et al: SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. J Biol Chem 274:27583-27589, 1999
73. Koul D, Jasser SA, Lu Y, et al: Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 21:2357-2364, 2002
74. Mao M, Fang X, Lu Y, et al: Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochem J 352:475-482, 2000
75. Kiley SC, Welsh J, Narvaez CJ, et al: Protein kinase C isozymes and substrates in mammary carcinogenesis. J Mamm Gland Biol Neoplasia 1:177-187, 1996
76. Carter CA: Protein kinase C as a drug target: Implications for drug or diet prevention and treatment of cancer. Curr Drug Targets 1:163-183, 2000
77. Fang X, Yu S, Tanyi JL, et al: Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22:2099-2110, 2002
78. Siminovitch KA, Lamhonwah AM, Somani AK, et al: Involvement of the SHP-1 tyrosine phosphatase in regulating B lymphocyte antigen receptor signaling, proliferation and transformation. Curr Top Microbiol Immunol 246:291-297, 1999
79. Campbell RA, Bhat-Nakshatri P, Patel NM, et al: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem 276:9817-9824, 2001
80. Sun M, Paciga JE, Feldman RI, et al: Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 61: 5985-5991, 2001
81. Barlund M, Monni O, Kononen J, et al: Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res 60:5340-5454, 2000
82. Adam L, Vadlamudi R, Kondapaka SB, et al: Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 273:28238-28246, 1998
83. Perez-Tenorio G, Stal O: Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86:540-545, 2002
84. Kim DH, Sarbassov DD, Ali SM, et al: mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163-175, 2002
85. Raught B, Gingras AC, Sonenberg N: The target of rapamycin (TOR) proteins. Proc Natl Acad Sci U S A 98: 7037-7044, 2001
86. Yu K, Toral-Barza L, Discafani C, et al: mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8:249-258, 2001
87. Mills GB, Lu Y, Kohn EC: Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci U S A 98:10031-10033, 2001
88. Neshat MS, Mellinghoff IK, Tran C, et al: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98:10314-10319, 2001
89. Podsypanina K, Lee RT, Politis C, et al: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 98:10320-10325, 2001
90. Geoerger B, Kerr K, Tang CB, et al: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61:1527-1532, 2001
91. Vinals F, Chambard JC, Pouyssegur J: p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J Biol Chem 274:26776-26782, 1999
92. Zhong H, Chiles K, Feldser D, et al: Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545, 2000
93. Shi Y, Wang R, Sharma A, et al: Dissociation of cytokine signals for proliferation and apoptosis. J Immunol 159: 5318-5328, 1997
94. Green DR, Evan GI: A matter of life and death. Cancer Cell 1:19-30, 2002
95. Petricoin EF, Zoon KC, Kohn EC, et al: Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 1:683-695, 2002
96. Liotta LA, Kohn EC, Petricoin EF: Clinical proteomics: Personalized molecular medicine. JAMA 286:2211-2214, 2001